GTBP GT Biopharma Inc
2,288
$5.02
$0.58
(10.36%)
| Watchers | 2,288 |
| 52-Wk Low | $2.95 |
| 52-Wk High | $16.11 |
| Market Cap | $7.11M |
| Volume | 895,092.00 |
| 52-Wk High | $16.11 |
| 52-Wk Low | $2.95 |
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the Company ), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
GT Biopharma, Inc. (NASDAQ:GTBP Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 58,800...
GT Biopharma (NASDAQ:GTBP Get Free Report) and PaxMedica (NASDAQ:PXMD Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the...